Details
Category: Volume 06 Issue 05 May 2018
Hits: 1178

Title: A prospective Study of Idiopathic Familial Hyperphosphatasia ''Juvenile Paget's Disease'' guide line of support diagnosis plus managements with different modalities of treatments depend on improvement criteria

Author: Ahmed Alkhuzai FICMS

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i5.148

Abstract

Background: Idiopathic Hyperphosphatasia` (IFH, also known as juvenile Paget’s disease) is a rare genetic bone disease characterized by very high bone turnover and progressive bony deformity. Treatment by different medical modalities Have advantages to control this disease, as Inhibitors of bone resorption, plus suppression of bone turnover.

Aim of Study: We assess the clinical, diagnostic criteria, plus evaluation of treatment of this rare condition with different modalities of conservative and required surgical procedures. Advantages in control these diseases and prevention the development of deformity and disability, were evaluated on improvement criteria.

Materials and Methods: A prospective descriptive study was performed on five cases of Familial Idiopathic Hyperphosphatasia, patients in the study A; 10 years age, from Baghdad B; also, from Baghdad, the sister of patient A, 7 years age, C; 8 years age girl from Anbar, D; 11 years girl from Wasit, E; 9 years age boy from Sulaimaniyah. They were from Different Cities of Iraq. Presented with progressive deformities, progressive hearing loss deafness, cranial enlargement, teeth loss, long bone fractures. Also, with diagnostic radiological changes plus biochemical abnormalities, in form persistent elevated ALK. Alkaline Phosphatase, PTH Parathyroid Hormone, with drop in Vitamin D3 level. Also, they have bone biopsy change. These criteria with different treatment modalities improved the diagnosis plus managements. We have different treatment modalities; Synthetic Calcitonin, Bisphosphonate, Sodium Etidronate, pamidronate, cholcalciferol. We used the Synthetic Calcitonin therapy daily 100mg once daily as conservative preventive measure, plus cholcalciferol. The surgical Orthopaedic treatment in form fixation of the fractures when happen, Stapling of Epiphysis as Hemiepiphyseal Stapling for Knee joint correction of the deformities in Children for prevention the progressiveness of long bone deformity. We used Calcitonin injection therapy, plus cholcalciferol, was given to arrest progression of the skeletal deformities of the disease. Growth and development, pure tone audiometry, biochemistry, radiology, densitometry (DXA), and bone histology were monitored.

Results: All patients with FIH cases were treated by Calcitonin subcutaneous injection of 100 mg daily as subcutaneous injection, therapy was given over 6 months with continuous follow up until skeletal maturity. Treatment was well tolerated, and the biochemical markers of bone turnover suppressed to within the age-appropriate normal range After 3 consecutive months. Improvement Criteria; Child become more Active- Less Irritable, Can't Sit Without Assistance, Formation of Discrete Cortex in Long Bones, Drop Level of Alkaline Phosphatase, Inhibition of Osteocytic Osteolysis Leading to Normal Lamellar Bone. The plasma ALP activity was suppressed to 295 U/liter, with continue to drop down continuously. However, before treatment the level was 480-677 U/L for these five patients. Radiography before treatment, there were marked spinal osteoporosis with vertebral biconcavity and a marked upper thoracic kyphoscoliosis. There was little improvement in vertebral shape, but no crush fractures occurred, also there was some progression of thoracic kyphosis for all cases without significant value. However, they had no further fractures occurred over the 3-yearsperiod happen during treatment, and all five IFH Idiopathic Familial Hyperphosphatasia remained mobile and active during performing daily activities, with improvement in skeletal development, plus preventing progressiveness of long bone deformities.

Conclusions: We have concluded that subcutaneous daily injectable Calcitonin therapy treatment can efficiently prevent the development of deformity, and disability, plus improvement in the hearing in children efficiently with IFH, also improvement in general condition, the child become more active, the dose of subcutaneous daily injectable Calcitonin therapy greater than usual doses were used in pediatric bone disease, with no adverse effects, in particular on bone mineralization.

Keywords: IFH; Idiopathic Familial Hyperphosphatasia, juvenile Paget’s disease, bisphosphonates.

References

  1. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAllister WH, Mumm S 2002 Osteoprotegerin deficiency and juvenile Paget’s disease. N Engl J Med 247:175–184.
  2. Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, Tau C, Tuysuz B, Yuksel B, Love D, Cundy T 2003 Idiopathic hyperphosphatasia: Relationships between phenotype and mutations in the gene encoding osteoprot-egerin. J Bone Miner Res 18:2095–2104.
  3. Doyle FH, Woodhouse NJY, Glen ACA, Joplin GF, MacIntyre I 1974 Healing of the bones in juvenile Paget’s disease treated by human calcitonin. Br J Radiol 47:9–15.
  4. Horwith M, Nunez EA, Krook L, Viteri F, Torun B, Mena E, Suh SM, Eisenberg E, MacIntyre I, Whalen JP 1976 Hereditary bone dysplasia with hyperphosphatasemia: response to synthetic human calcitonin. Clin Endocrinol (Oxf) 5(Suppl):341S–352S.
  5. Whalen JP, Horwith M, Krook L, MacIntyre I, Mena E, Viteri F, Torun B, Nunez EA 1977 Calcitonin treatment in hereditary bone dysplasia with hyperphosphatasemia: A radiographic and histologic study of bone. Am J Roentgenol 129:29–35.
  6. Blanco O, Stivel M, Mautalen C, Schajowicz F 1977 Familial idiopathic hyperphosphatasia. J Bone Joint Surg Br 59:421–427.
  7. Dunn V, Condon VR, Rallison ML 1979 Familial hyperphosphatasemia: Diagnosis in early infancy and response to human thyrocalcitonin therapy. Am J Roentgenol 132:541–545.
  8. Spindler A, Berman A, Mautalen C, Ubios J, Santini EA 1992 Chronic idiopathic hyperphosphatasia: Report of a case treated with pamidronate and a review of the literature. J Rheumatol 19:642–645.
  9. Cassinelli HR, Mautelen CA, Heinrich JJ, Miglietta A, Bergada C 1992 Familial idiopathic hyperphosphatasia: Response to longterm treatment with pamidronate. Bone Miner 19:175–184.
  10. Singer F, Siris E, Shane E, Dempster D, Lindsay R, Parisien M 1994 Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. J Bone Miner Res 9:733–738.
  11. Golob DS, McAlister WH, Mills BG, Fedde KN, Reinus WR, Teitelbaum SL, Beeki S, Whyte MP 1996 Juvenile Paget disease: Life-long features of a mildly affected young woman. J Bone Miner Res 11:132–142                            
  12. Tu ¨ysu ¨z B, Mercimek S, Unger S, Deniz M 1999 Calcitonin treatment in osteoectasia with hyperphosphatasia (juvenile Paget’s disease). PediatrRadiol 29:838–841.
  13. Demir E, Bereket A, Ozkan B, Topcu M 2000 Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab 13:217–221
  14. Tuysuz B, Mercimek S, Ungur S, et al; Calcitonin treatment in osteoectasia with hyperphosphatasia (juvenile Paget's disease): radiographic changes after treatment. PediatrRadiol. 1999 Nov29(11):838-41
  15. Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293– 1299.
  16. Eroglu M, Taneli NH 1976 Congenital hyperphosphatasia (juvenile Paget’s disease). Ann Radiol 20:145–150.
  17. Bonakdarpour A, Maldjian C, Weiss S, Roach N, Stein E 2000 Hyperphosphatasemia: Report of three cases. Eur J Radiol 35:54– 58.
  18. Kanis JA, Henderson RG, Heynen G, Ledingham JGG, Russell RGG, Smith R, Walton RJ 1977 Renal osteodystrophy in nondialysed adolescents: Long-term treatment with 1 - hydroxycholecalciferol. Arch Dis Child 52:473–481.
  19. Fleisch H 1995 Bisphosphonates in Bone Disease—From the Laboratory to the Patient. Parthenon Publishing, New York, NY, USA.
  20. Grauer A, Heichel S, Knaus J, Dosch E, Ziegler R 1999 Ibandronate treatment in Paget’s disease of bone. Bone 24(Suppl):87S– 89S.
  21. Kanis JA 1991 Pathophysiology and Treatment of Paget’s Disease of Bone. Martin Dunitz, London, UK.
  22. Monsell EM, Cody DD, Bone HG, Divine GW, Winham JP, Jacobson GP, Newman CW, Patel SC 1995 Hearing loss in Paget’s disease of bone: The relationship between pure-tone thresholds and mineral density of the cochlear capsule. Hear Res 83:114–120.
  23. Viereck V, Emons G, Lauck V, Frosch K-H, Blaschke S, Grundker C, Hofbauer LC 2002 Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680–686.

Corresponding Author

Ahmed Alkhuzai FICMS

Faculty of Medicine Sulaimani University/Iraq